Howard, as "Analyst X" is you, don't you consider making up the following and posting it to misc.invest.stocks to be a deliberate attempt at stock manipulation? And like Cyanotech will you first hype and then trash the stock under a number of different aliases?
Good luck with Quidel to everyone else on this thread.
Patrick (have no Quidel, but am a Trinity Biotech holder)
xp8.dejanews.com
The following are earnings estimates for Quidel Corp (NASDAQ--QDEL) from
the independent Analyst X advisory service. Standard disclaimers are in
force.
4 th Quarter FY 1996: Analyst X - .06 vs. .01 (Industry Estimate is .06)
1st Quarter FY 1997: Analyst X - .04 vs. .01 (Industry Estimate is .04)
Price based on P/E = 40 is $6.40/share by MAY 1997
Remaining quarterly estimates are subject to uncertainty:
2nd Quarter of 1997: Analyst X - .12 vs. .08 (Industry Estimate is .04)
3rd Quarter of 1997: Analyst X - .10 vs. .06 (Industry Estimate is .04)
Fiscal Year of 1997: Analyst X - .30 vs. .16 (Industry Estimate is .21)
Price based on P/E = 40 is $12.00/share
Factors Considered in Estimate:
* Quidel Corp recently entered into a partnership with Proctor and
Gamble Corp to market a rapid testing kit for the bacteria which causes
ulcers in 80% of cases. Quidel Corp has the only "CLIA-waived" test kit
for this bacteria in the marketplace.
* Quidel Corp is now above "break-even" for the first time in it's
history. The lastr quarter showed a 300% gain in earnings on much
improved revenues, mainly from the company's rapid test kit for strep
throat. Last quarter's earnings were .08 vs. .02.
* The company is in a highly leveraged position, with 50 cents of each
dollar after 9 million in revenues going to the bottom line.
* Experience shows that two strong quarter's in a row attract
institutional attention to stocks from analysts in the industry. In
addition, once share price reaches $10, institutional investors will
be able to take a position in the stock.
* R&D is strong, the company has plenty of cash, and new products should
be announced within the year, providing rapid testing for other ailments.
As always, Analyst X is not paid by any industry, company or brokerage
house. His opinions are the result of 10 successful years in the equity
markets. Please do your own research before investing. www.quidel.com
is the company home page.
OTHER Current Analyst X Recommended stocks: Cyanotech (CYAN), AT&T (T),
Micron Electronics (MUEI), Iomega (IOM)
Recommended SHORT Positions: America Online (AOL), US Robotics (USRX),
Transworld Airlines (TWA). |
